Register for our free email digests:
Latest From Proacta Inc.
The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.
Following a setback earlier this year, the privately held Japanese bioventure LivTech has bounced back with a new deal for one of its main streams of research, signing an option agreement with Yakult Honsha for a series of novel anticancer antibodies.
Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Guerbet SA
- Senior Management
Yves L'Epine, CEO
Jean-Francois Le Martret, CFO
- Contact Info
Phone: (33) 1 45 91 50 00
Rue des Vanesses, 15
P.O. Box 50400 Villepinte, 93420
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.